Clinical trials: Lenalidomide
Multiple Myeloma
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
The primary purpose of this study is to estimate the overall response rate (ORR), defined as partial response (PR) or better at any time during induction therapy.
- Trial name
- NCT01729338
- Testing
- Velcade, Cyclophosphamide, Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Multiple Myeloma
High Dose Carfilzomib for Newly Diagnosed Myeloma
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients.
- Trial name
- NCT02937571
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
The purpose of the study is to learn about the effects of the drug, lenalidomide (Revlimid®), on neuropathy (damage to the nerves that affect feelings and strength) associated with Nonmalignant Monoclonal Gammopathy of…
- Trial name
- MGUS (NCT00665652)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Myeloma
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MRD (NCT00679367)
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boston Medical Center
Multiple Myeloma, Non-Hodgkin's Lymphoma
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested.
- Trial name
- NCT01755975
- Testing
- Romidepsin, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Multiple Myeloma
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
- Trial name
- NCT00603447
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Amgen
Diffuse Large B-cell Lymphoma
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
- Trial name
- NCT01197560
- Testing
- Lenalidomide, Gemcitabine, Oxaliplatin
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 111 people
- Sponsor
- Celgene
Plasma Cell Myeloma, Residual Disease
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell…
- Trial name
- NCT02389517
- Testing
- Ixazomib Citrate, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell…
- Conditions
- Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
- Trial name
- NCT02309515
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
The purposes of this study are to: find out whether participants' cancer returns or gets worse while they are taking lenalidomide and Bacille Calmette-Guerrin (BCG); evaluate the safety and tolerability of the combination of…
- Trial name
- NCT01373294
- Testing
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory…
- Trial name
- NCT01564537
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 24 sites in United States, Canada
- Volunteers
- 722 people
- Sponsor
- Takeda
Myelodysplastic Syndrome
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
Multi-center, survival data collection in subjects previously enrolled in study NCT00065156 (Celgene Protocol CC-5013-MDS-003).
- Trial name
- NCT01099267
- Where
- 15 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Celgene
Myelodysplastic Syndromes, Thrombocytopenia
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS)…
- Trial name
- NCT00418665
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in patients who have already…
- Trial name
- NCT00759603
- Testing
- Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center